TrialMultiple sclerosis (Houndmills, Basingstoke, England)2020

Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.

Rafael Arroyo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.